- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03617198
CD4 CAR+ ZFN-modified T Cells in HIV Therapy
A Pilot Study of T Cells Genetically Modified by Zinc Finger Nucleases SB-728mR and CD4 Chimeric Antigen Receptor in HIV-infected Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Step 1:
Subject is screened, undergoes leukaphereses, and optional rectal biopsy, and safety evaluations before dosing. The University of Pennsylvania manufactures the study product.
Step 2:
Subjects receive a single infusion of 0.5-1x10(10) CD4 CAR+CCR5 ZFN modified T cells. Cohort 2 participants undergo a mini-leukapheresis and optional rectal biopsy at the end of step 2.
The duration of Step 2 will be:
- Cohort 1: 1 day
- Cohort 2: 8 weeks
Step 3:
All subjects will participate in a 16 week analytical treatment interruption (ATI). ATI will be less than 16 weeks if patient's viral load is sustained >100,000 or CD4 count <350 or less than 50% of baseline. At the end of step 3 all participants will undergo mini-leukapheresis and optional rectal biopsy.
Step 4:
Participants who have HIV viral loads ≤1000 copies/ml will continue in an extension of the analytical treatment interruption until viral load is sustained >100,000 or CD4 count <350 or less than 50% of baseline.
Step 5:
Reinitiation of antiretroviral therapy with monthly visits until the HIV RNA is below the limit of quantification. All participants undergo a mini-leukapheresis and optional rectal biopsy at the end of the step 5.
Step 6 (Secondary Follow-up):
All subjects will be followed for safety for up to 5 years post-infusion.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- HIV-1 infection
- Clinically stable on first or second HAART regimen
- Screening CD4+ T cell count of ≥450 cells/mm3 within 30 days of enrollment; and a documented CD4 nadir of not lower than 200 cells/mm3
- Screening HIV-1 RNA that is ≤50 copies/mL within 30 days prior to enrollment
- HIV-1 RNA ≤50 copies/mL for at least 24 weeks prior to enrollment
- Adequate venous access and no other contraindications for leukapheresis
- Laboratory values within certain parameters, obtained within 30 days prior to enrollment
- Willing to comply with study-mandated evaluations
- Male or female, 18 years of age or older
- Ability and willingness to provide informed consent
- Karnofsky Performance Score of 70 or higher
- Negative HBsAg (hepatitis B) within 6 months prior to enrollment
- Negative HCV (hepatitis C) serology, or if positive, negative HCV RNA within 6 months prior to enrollment
- Have a recorded viral load set point prior to starting antiretroviral therapy
Exclusion Criteria:
- Acute or chronic hepatitis B or hepatitis C infection
- Current or prior AIDS diagnosis
- History of cancer or malignancy, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin
- History or any features on physical examination indicative of active or unstable cardiac disease or hemodynamic instability (subjects with a history of cardiac disease may participate with a physician's approval)
- History or any features of physical examination indicative of bleeding diathesis
- Have been previously treated with any HIV experimental vaccine within 6 months prior to screening, or any previous gene therapy using an integrating vector (subjects treated with placebo in an HIV vaccine study will not be excluded if documentation that they received placebo is provided)
- Use of chronic systemic corticosteroids, hydroxyurea, or immunomodulating agents within 30 days prior to enrollment (recent or current use of inhaled steroids is not exclusionary)
- Breast-feeding, pregnant, or unwilling to use acceptable methods of birth control
- Anticipated use of aspirin, dipyridamole, warfarin, or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2 week period prior to leukapheresis
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
- Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to the study screening visit
- Receipt of vaccination within 30 days prior to study screening visit
- Have an allergy to hypersensitivity to study product components (human serum albumin, DMSO and Dextran 40)
- Currently taking a non-nucleoside reverse transcriptase inhibitor (NNRTI)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells.
All other study procedures are the same as Cohort 2.
|
A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
|
Experimental: Cohort 2
Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells.
All other study procedures are the same as Cohort 1.
|
A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with treatment related adverse events.
Time Frame: After subjects have received infusion and up to 5 years from Day 0 infusion.
|
After subjects have received infusion and up to 5 years from Day 0 infusion.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare the percentage of enriched modified CD4 CAR+ CCR5 ZFN cells and their subsets.
Time Frame: 2 weeks post infusion, prior to prior to analytical treatment interruption (ATI), 6-9 months post infusion.
|
2 weeks post infusion, prior to prior to analytical treatment interruption (ATI), 6-9 months post infusion.
|
Compare the change in CD4 count.
Time Frame: Baseline, week 2 post infusion, prior to ATI, weeks 8, 12, 16 of ATI.
|
Baseline, week 2 post infusion, prior to ATI, weeks 8, 12, 16 of ATI.
|
Compare viral set point log 10 HIV RNA level.
Time Frame: Baseline and 6-9 months post infusion
|
Baseline and 6-9 months post infusion
|
Percentage of cells producing cytokines in response to HIV antigen/peptide as assessed by flow cytometry
Time Frame: Baseline and 6-9 months post infusion
|
Baseline and 6-9 months post infusion
|
Size of latent HIV reservoir as assessed by quantification of integrated copies of replication competent HIV
Time Frame: Baseline, pre-treatment interruption, prior to ART reinitiation, 6-9 months post infusion, and end of primary follow up (8-12 months)
|
Baseline, pre-treatment interruption, prior to ART reinitiation, 6-9 months post infusion, and end of primary follow up (8-12 months)
|
Sequence of HIV envelope genes and coreceptor usage in breakthrough HIV infections
Time Frame: Baseline through 1 year.
|
Baseline through 1 year.
|
Number of participants who control HIV replication that have similar gene expression patterns as determined by RNA quantification
Time Frame: Baseline through 1 year.
|
Baseline through 1 year.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pablo Tebas, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 831464
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on CD4 CAR+CCR5 ZFN T-cells
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingRefractory T-Cell Lymphoma | T Cell Lymphoma in RelapseChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States